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Abstract
Hepatosplenic γδ T-cell lymphoma (HSTCL)
is a very rare peripheral T-cell lymphoma char-
acterized by extranodal infiltration of mature
malignant  post-thymic  T-lymphocytes  into
sinusoids of the liver and spleen without lym-
phadenopathy and significant cytopenias. The
aetiology  of  the  disease  is  unknown.  We
describe the case of a female patient in whom
HSTCL developed after delivery and who was
previously without disease. Flow cytometry and
liver  puncture  are  essential  for  diagnosing
HSTCL, especially in patients with unexplained
pancytopenia  and  hepatosplenomegaly.  Since
phenotypic results can easily be misinterpreted
as non-malignant, the examiner should have
enough experience to recognize clonal changes
of T-lymphocytes. Namely, in contrast to B-lym-
phocytes, T-lymphocytes do not have an effi-
cient indicator of clonality and are recognized
by  flow  cytometry  based  only  on  aberrant
expression of commonly present antigens of T-
cell and NK-cell subsets. At present, there is no
known cure for HSTCL with a maximum sur-
vival up to 2 years. 
Introduction
Hepatosplenic γδ T-cell lymphoma (HSTCL)
is a rare peripheral T-cell lymphoma with pre-
dominant occurrence in young male adults and
characterized  by  extranodal  infiltration  of
mature malignant post-thymic T-lymphocytes
into sinusoids of the liver and spleen without
lymphadenopathy and significant cytopenias.1
Increased numbers of normal γδ T-cells can be
found in patients with chronic antigen stimu-
lation, autoimmune disease, post solid organ
transplantation (kidney, liver) and splenecto-
my. A precise phenotype of γδ T-lymphocytes
has  not  been  described  until  recently.2
Malignant neoplasms arising from γδ T-lym-
phocytes  are  very  rare.  Among  those,  the
HSTCL represents <5% of peripheral T/ NK-
lymphomas,  and  is  less  common  than  αβ
peripheral T cell lymphoma.3 Only 150 cases
have been described in literature since the ini-
tial description by Farcet and Gaulard in 1990. 
Case Report
A 20-year old patient was admitted to the
Department of Haematology for clarification of
haematomata  in  both  hands,  hepatosple-
nomegaly  and  pancytopenia.  No  enlarged
lymph nodes were palpated. Three months ago
she had a normal delivery of a healthy female
baby. She had a normal pregnancy. She has
never taken any contraceptives or other med-
ication and previously she was healthy. During
pregnancy  her  blood  work  was  normal.  Two
months before admittance to our department
she first noticed haematomata in extremities,
and more recently she had become tired, dizzy
and pale. She did not have a fever and did not
lose weight. Clinical examination revealed an
enlarged liver and spleen (15 cm) besides pale-
ness and haematomata in her extremities. No
enlarged  lymph  nodes  were  palpated.  Blood
test  revealed  pancytopenia  (red  blood  cells
(RBC) 3,5ﾥ1012/ L, haemoglobin (Hb) 91 g/L,
reticulocytes  85ﾥ109/L,  white  blood  cells
(WBC) 3,4ﾥ109/L with 7% of atypical lympho-
cytes, platelets 28ﾥ109/L, elevated total biliru-
bin  (28  ʼmol/L)  and  C  reactive  protein  (22
mg/L), low cholinesterase (CHE) 92 ʼkat/L and
prothrombin  time  0,55  E,  other  blood  tests
(aspartate  transaminase  (AST),  alanine
transaminase (ALT), urea, creatinine, lactate
dehydrogenase  (LDH),  vitamin  B12,  folates,
electrolytes, tumour markers and immunologi-
cal markers) were within normal limits. Viral
and  bacterial  serology  was  performed  (toxo-
plasmosis,  cytomegalovirus,  tularaemia,  HIV,
Wassermann  test,  Yersinia,  human  her-
pesvirus, Epstein-Barr virus (EBV), hepatitis)
and showed the presence of antibodies to EBV
(Table 1). Lung and heart x-rays were normal.
Ultrasound and abdominal computed tomogra-
phy (CT) showed a slightly enlarged liver with
a homogeneous pattern and markedly enlarged
spleen  reaching  into  the  pelvis,  bulging  the
anterior abdominal wall, pressing onto stom-
ach and left kidney and pushing the left liver
lobe  away.  There  were  no  enlarged  lymph
nodes (Figure 1). Because of the suspicion of
a blood disease, we performed a bone marrow
phenotyping,  which  showed  a  population  of
CD3+ lymphocytes  expressing  CD56+,  CD16
partly+, CD38+, CD8 low+, CD2+, CD7+ but not
CD5– or TdT–. Of the additionally tested anti-
gens, CD45RO and CD161 were positive, how-
ever the intracellular granzyme B was negative
(Figure  2).  This  population  with  aberrant
expression of antigen CD5 and low expression
of antigen CD8 (in Figure 3 appearing red)
presented 16% of leukocytes, 70% of all lym-
phocytes and 77% of T-lymphocytes in the bone
marrow  sample.  The  immunophenotyping
results caused suspicion for the involvement of
the extremely rare γδ hepatosplenic lymphoma
that was later confirmed by liver puncture. The
liver puncture revealed that the liver was dif-
fusely infiltrated with lymphoma cells which
were  typically  distributed  in  the  sinusoids
instead of in the portal tracts as seen in usual
lymphomas. The nuclei of the lymphoid cells
were round, ovoid, occasionally irregular with
quite dense chromatin, and a small amount of
pale to clear cytoplasm (Figure 3). Lymphoma
cells were immunohistochemically highlighted
with T-lineage markers. A bone biopsy revealed
similar  cells.  The  patient  was  treated  with
high-dose chemotherapy (CHOP) and autolo-
gous bone-marrow transplant. Signs of disease
progression  (pancytopenia,  spleen-growth
reaching into pelvis) appeared after one year
with B-signs. A specific oncological treatment
was not decided upon.
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Discussion
Although the aetiology of the HSTCL is still
unknown, approximately 10% to 20% of affect-
ed patients have a previous history of immuno-
compromise, including solid organ transplant
(renal,  liver,  heart),  inflammatory  bowel  dis-
ease  (mostly  Crohn's  disease),  hepatitis  B
infection,  or  the  patients  have  been  treated
with immunosuppressive therapy (e.g. due to
rheumatoid  arthritis,  systemic  lupus  erythe-
matosus). Generally it is not associated with
EBV.4,5 It can occur during pregnancy.6 To date
it was not described after delivery.6 HSTCL was
also described in animals. It has been estab-
lished that during pregnancy the placenta con-
tains more NK cells, αβ T cells and γδ T-cells,
which express more cytotoxic molecules than
T-cell intracellular antigen 1, granzyme B and
especially perforin. It is assumed that during
pregnancy  the  high  progesterone  concentra-
tion might affect the perforin expression and
that maternal immunity and hormonal changes
during  pregnancy  and  presumably  delivery
might eventually provide a chance for decidual
lymphocytes to transform and develop HSTCL.7
The leading sign of HSTCL is hepatosple-
nomegaly  and  cytopenia,  while  lymph  node
enlargement  excludes  the  disease.  However,
other  clinical  features  like  fatigue,  Coombs
negative haemolytic anaemia, jaundice due to
hepatic  involvement  and  purpura  due  to
thrombocytopenia may occur. The main sign of
the  disease  is  blood  cell  reduction,  ranging
from isolated reduction of one lineage to pan-
cytopenia as a consequence of hypersplenism
and/or suppression of bone marrow precursor
cells by cytokines released by neoplastic cells.
The  most  obvious  appears  to  be  thrombocy-
topenia. The blood smear is usually normal, a
leukemic picture or lymphocytosis can yet be
found, or, as in our case, a minor population of
atypical lymphocytes. Elevated LDH or changes
in  liver  enzymes  are  also  possible.  All  the
above mentioned clinical and laboratory tests
are non-specific and if not recognized they can
lead to misdiagnosis of virus infection (mostly
EBV), immune thrombocytopenia or acute lym-
phoblastic leukaemia.8
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Table 1. Patient’s laboratory data.
Parameter, units Patient Reference values
WBC , Eﾥ109/L 3,4 4,0-10,0
Blood smear, % 
Segmented neutrophils 45 40-60
Banded neutrophils 3 0-3
Lymphocytes 36 20-40
Monocytes 9 2-8
RBC , Eﾥ1012/L 3,5 4,2-6,3
Hb, g/L  91 120-180
MCV, fl 79 81-94
Reticulocytes, Eﾥ109/L 85,1 21-94
Platelets , Eﾥ109/L 28 140-340
Biochemistry 
AST, ￿ʼkat/L 0,15 0-0,58
ALT , ʼkat/L 0,23 0-0,74
CHE, ʼkat/L 118 117-317
Total bilirubin, ￿ʼmol/L 30 0 -17
Urea, mmol/L 5,3 2,8-7,5
Creatinine, mmol/L 71 44-97
Folic acid, ʼ￿mol/L 12,9 6,1-32,6
B12, ￿pmol/L 114 132-857
CRP, mg/L 4 0 -5
LDH, ʼkat/L 1,05 0-4,13
Prothrombin time, E 0,55 0,7-1,2
ANA, ANCA, ACA, AMA  negative negative
CA 19-9, CA 15-3, CEA, ￿αFP negative negative
Serological tests
Toxoplasmosis, CMV,  Yersinia, EBV (IgG 1: 160, IgM 1:10,
Human herpesvirus, EBV EBNA 1: 10), other negative
Hepatitis A, B, C, HIV negative negative
Wasserman test negative negative
MCV, mean corpuscular volume; ANA, antinuclear antibody; ANCA, anti- neutrophil cytoplasmatic antibody; ACA, anti-centromere antibody;
AMA, anti-mitochondrial antibody; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
Figure  1.  Computer  tomography  of  the
patient's abdomen, transverse scan. L, left;
R,  right;  S,  very  enlarged  spleen;  LIV,
enlarged liver
Figure 2. Flow cytometry in our patient:
population of 77 % CD3+ T-lymphocytes
are marked red on the CD 45 - SSC dia-
gram (phenotype CD56+, CD16 partial-
ly+,  CD38+,  CD8  low+,  CD2+,  CD7+,
CD5–, TdT–, CD45RO+, CD161+, intra-
cellular granzyme B negative).
Figure  3.  Liver  histology  of  our  patient
shows  lymphoma  cells  (arrow)  between
hepatocytes (star) (Haemotoxylin - Eosin
stain, x400). [page 14] [Hematology Reports 2012; 4:e4]
To  diagnose  HSTCL,  a  flow  cytometric
immunophenotyping of lymphocytes and liver
biopsy is sufficient.3 Flow cytometric immuno-
phenotyping is extremely helpful in diagnos-
ing,  however  both,  the  diagnostic  and  the
examiner,  should  be  experienced  enough  to
recognize  clonal  changes  of  T-lymphocytes.
Unlike  B-lymphocytes,  T-lymphocytes  do  not
have an efficient indicator of clonality on the
membrane, so they can be recognized by flow
cytometry based only on aberrant expression of
usually present antigens of the T-cell and NK-
cell  subsets.9 Malignant-changed  T-lympho-
cytes, including the rare-ones, can often be rec-
ognized, since the antigen of the T-cell subset
can  be  completely  absent  or  its  intensity  of
expression  has  changed  when  compared  to
other normal-polyclonal T lymphocytes. HSTCL
commonly has the phenotype described in our
patient.3,8 There  are  also  exceptions  to  the
common phenotype, since expression of CD5,
CD7, CD8, CD16 and CD56 is variable. Antigens
characteristic for B-lymphocytes (CD19, CD20,
CD21, and CD22), immunoglobulins, TCR αß-
chain, TdT, CD10, CD15, CD25, CD33, CD34,
CD41, and CD68 are not expressed.10 A special
subcategory shows αß TCR expression as well
as clinical and pathologic features that resem-
ble those of HSTCL. Based on the flow cytome-
try of our patient's bone marrow aspirate we
were able to establish the phenotype of cells-
suspicious for HSTCL in a few hours, which
was later additionally confirmed by the bone
and liver biopsy. Since the bone marrow exam-
ination with regular staining does not show the
cells typical for this disease (however the flow
cytometry does reveal the phenotype suspicious
for HSTCL), it is recommended to additionally
perform  immunohistochemical  staining  tests
for T-lymphocytes, which reveal a hypercellular
bone marrow with a sinusoidal infiltration of
atypical,  medium  sized  lymphoid  cells  with
abundant light and basophilic cytoplasm and
multiple granulations.1,11 Both, liver and spleen
puncture, reveal sinusal infiltration with atypi-
cal  lymphocytes.  The  splenic  white  pulp  is
reduced or completely lost. Since the normal γδ
T-lymphocytes have special homing receptors
for splenic sinuses it is most likely that the
HSTCL originates in the splenic red pulp.1 A
special  phenomenon  is  erythrophagocytosis
documented  in  areas  invaded  by  malignant
cells.  Mostly  in  male  patients  cytogenetic
changes can occur (isochromosome 7q, trisomy
8 or absent Y-chromosome), but this is not suf-
ficient to define the disease.8 Differential diag-
nosis  should  exclude  other  rare  T-cell  lym-
phomas/leukaemia (T-lymphoblastic lymphoma
expressing TCR γδ, peripheral cytotoxic T-cell
lymphomas  and  unusual  forms  of  T  chronic
lymphocytic/promyelocytic leukaemia with CD8
phenotype); however all these entities usually
express TCR αβ chains.8
HSTCL is an extremely aggressive disease
with  median  survival  rate  of  8  months  to  a
maximum of 2 years, with possible remission
due to treatment. At the present time an effec-
tive treatment of HSTCL is lacking, as treat-
ment modalities for other lymphoma appear to
be ineffective in most patients. Moreover there
is no known biomarker for the prediction of a
prognosis. A wide array of therapies have been
used, including steroid or alkylating treatment,
purine  analogs,  splenectomy  and  high  dose
chemotherapy with or without allogeneic stem
cell transplantation.12,13Prolonged disease free
survival  has  been  reported  in  patients  who
underwent  allogeneic  stem  cell  transplanta-
tion, receiving combined treatment with cyto-
statics and alemtuzumab, as pralatrexate and
romidepsin  for  progressive  or  relapsed
HSTCL.14-17
Conclusions
HSTCL is a rare entity of T-cell lymphoma,
uncommon in female patients and not report-
ed after delivery so far. The majority of patients
presents with hepatosplenomegaly, bone mar-
row infiltration and cytopenia. Flow cytometry
is essential in diagnosing HSTCL rapidly, and
should additionally be confirmed by bone mar-
row examination and liver and/or spleen punc-
ture. Since it is a rare disease the examiner
should have enough experience to recognize
clonal changes of T-lymphocytes. The patient’s
fate,  however,  lies  in  good  cooperation
between  departments,  diagnostic  laboratory
for flow cytometry and eventually the patholo-
gist. Cooperation is the only way to diagnose
this rare condition soon enough to help the
patient. 
References
1. Belhadj K, Reyes F, Farcet JP, et al. Hepa-
tosplenic  γδ T  -cell  lymphoma  is  a  rare
clinicopathologic  entity  with  poor  out-
come: report on a series of 21 patients.
Blood 2003;102:4261- 9.
2. Roden  AC,  Morice  WG,  Hanson  CA.
Immunophenotypic  attributes  of  benign
peripheral blood gammadelta T cells and
conditions associated with their increase.
Arch Pathol Lab Med 2008;132:1774-80.
3. Vega  F,  Medeiros  J,  Gaulard  P.  Hepato-
splenic and other γδ T -cell lymphomas.
Am J Clin Pathol 2007;127:869 -80.
4. Steurer M, Stauder R, Grunewald K,,et al.
Hepatosplenic  gamma/delta  lymphoma
with  leukemic  course  after  renal  trans-
plantation. Hum Pathol 2002;33:253-8.
5. Beigel  F,  Jürgens  M,  Tillack  C,  et  al.
Hepatosplenic  T  cell  lymphoma  in  a
patient  with  Crohn's  disease.  Nat  Rev
Gastroenterol Hepatol 2009;6:433 -6.
6. Niitsu  N,  Kohri  M,  Togano  T,  et  al.
Development  of  hepatosplenic  γδ T  cell
lymphoma with pancitopenia during early
pregnancy: a case report and review of the
literature. Eur J Haematol 2004;73:367-61.
7. Szekeres-Bartho J, Barakonyi A, Miko E, et
al. The role of gamma/delta T cells in the
feto-maternal relationship. Semin Immu-
nol 2001;13:229-33.
8. Tripodo C, Iannitto E, Florena AM, et al.
Gamma delta T cell lymphomas. Nat Rev
Clin Oncol 2009;6:707-17.
9. Stetler-Stevenson  M,  Braylan  RC.  Flow
cytometric analysis of lymphomas and lym-
phoproliferative disorders. Semin Hematol
2001;38:111-23.
10. Weidmann  E.  Hepatosplenic  T  cell  lym-
phoma. A review on 45 cases since the first
report describing the disease as a distinct
lymphoma entity in 1990. Leukemia 2000;
14:991-7.
11. Wei  SZ,  Liu  TH,  Wang  DT,  et  al.  Hepa-
tosplenic  γδ T-cell  lymphoma.World  J
Gastroenterol 2005;11:3729-34.
12. Falchook  GS,  Vega  F,  Dang  NH,  et  al.
Hepatosplenic  gamma  delta  T  cell  lym-
phoma:  clinicopathological  features  and
treatment. Ann Oncol 2009;20:1080-5.
13. Gumbs  AA,  Zain  J,  O'  Connor  OA.
Importance  of  early  splenectomy  in
patients  with  hepatosplenic  T  cell  lym-
phoma and severe thrombocytopenia. Ann
Surg Oncol 2009;16:2014-7.
14. Jaeger G, Bauer F, Brezinschek R, et al.
Hepatosplenic γδ T-cell lymphoma succes-
fully treated with a combination of alem-
tuzumab  and  cladribine.  Ann  Oncol
2008;19:1025-6.
15. Chanan-Khan  A,  Islam  T,  Alam  A,  et  al.
Long term survival with allogeneic stem
cell transplant and donor lymphocyte infu-
sion  following  salvage  therapy  with  anti
CD 52 monoclonal antibody (Campath) in
a patient with hepatosplenic α/βT cell non
Hodgkins lymphoma. Leuk Lymph 2004;45:
1673-5.
16. Study of pralatrexate with vitamin B12 and
folic  acid  in  patients  with  relapsed  or
refractory  peripheral  T-cell  lymphoma
(PROPEL).  Available  from:  http://clinical-
trials.gov/ct2/show/NCT00364923
17. A Trial of Romidepsin for Progressive or
Relapsed  Peripheral  T-cell  Lymphoma.
Available from: http://clinicaltrials.gov/ct2/
show/NCT00426764.
Case Report